(ACTION) Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas

Purpose

It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to kill the tumor.

In this research study, we will use a patient's tumor to make a vaccine which we hope will stimulate T-cells to kill tumor cells and leave normal cells alone.

Eligibility

  • 3 - 21 years old
  • Patients with histologically confirmed WHO Grade III or IV malignant glioma
  • Scheduled for definitive surgical resection of suspected HGG (biopsy only subjects are not eligible for this study)
For additional information about eligibility criteria, please contact the study coordinator Marcia Hodik: 

Procedures 

  • Drug: Temozolomide
  • Drug type: Chemotherapy

Full details regarding study procedures can be explained by the study coordinator Marcia Hodik: 

Age

N/A

Gender

Male
Female

Can be done from home

No

Keywords

Brain Tumors, Pediatric Brain Tumors, Brain Tumor, Brain tumor - children, Glioma

Principal Investigator

Elias Sayour, MD, PhD

Department

Neurosurgery

Contact Information

marcia.hodik@neurosurgery.ufl.edu

352.273.6971

Begin a new search for other research studies

Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at UFStudies@health.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams